Gupta Mansi, Rao Indu Ramachandra, Nagaraju Shankar Prasad, Bhandary Sulatha V, Gupta Jayanti, Babu Ganesh T C
Center of Application and Research in India, Carl Zeiss India (Bangalore) Pvt. Ltd, Bangalore, Karnataka, India.
Department of Nephrology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Int J Nephrol. 2022 Apr 29;2022:3922398. doi: 10.1155/2022/3922398. eCollection 2022.
A systematic search was conducted on PubMed, Embase, and the Google scholar for eligible studies through September 2021. The quality of selected articles was assessed using JBI checklist. Higgins and Thompson's statistic was used to see the degree of heterogeneity. Based on degree of heterogeneity, fixed or random effects model was used to estimate pooled effect using inverse variance method. Results were expressed as hazard ratios and odds ratios with 95% CIs.
After scrutinizing 18017 articles, data from ten relevant studies (seven prospective and three retrospective) was extracted. DR was significantly associated with DKD progression with a pooled HR of 2.42 (95% CI: 1.70-3.45) and a pooled OR of 2.62 (95% CI: 1.76-3.89). There was also a significant association between the severity of DR and risk of progression of DKD with a pooled OR of 2.13 (95% CI: 1.82-2.50) for nonproliferative DR and 2.56 (95% CI: 2.93-.33) for proliferative DR.
Our study suggests that presence of DR is a strong predictor of risk of kidney disease progression in DKD patients. Furthermore, the risk of DKD progression increases with DR severity. Screening for retinal vascular changes could potentially help in prognostication and risk-stratification of patients with DKD.
截至2021年9月,在PubMed、Embase和谷歌学术上进行了系统检索,以查找符合条件的研究。使用JBI清单评估所选文章的质量。采用希金斯和汤普森统计量来观察异质性程度。根据异质性程度,使用固定效应模型或随机效应模型,采用逆方差法估计合并效应。结果以风险比和比值比及95%置信区间表示。
在仔细审查18017篇文章后,提取了10项相关研究(7项前瞻性研究和3项回顾性研究)的数据。糖尿病视网膜病变与糖尿病肾病进展显著相关,合并风险比为2.42(95%置信区间:1.70 - 3.45),合并比值比为2.62(95%置信区间:1.76 - 3.89)。糖尿病视网膜病变的严重程度与糖尿病肾病进展风险之间也存在显著关联,非增殖性糖尿病视网膜病变的合并比值比为2.13(95%置信区间:1.82 - 2.50),增殖性糖尿病视网膜病变的合并比值比为2.56(95%置信区间:2.93 - 3.33)。
我们的研究表明,糖尿病视网膜病变的存在是糖尿病肾病患者肾病进展风险的有力预测指标。此外,糖尿病肾病进展的风险随着糖尿病视网膜病变严重程度的增加而增加。筛查视网膜血管变化可能有助于糖尿病肾病患者的预后评估和风险分层。